Reporting Uncertainty Around Health State Values: A Standard Method and Worked Example.

Objectives: Papers reporting value sets typically only report the standard errors (SEs) around each estimated coefficient in value set models. This is important information but does not help those building cost effectiveness models, who need to know the uncertainty around the values of health states in order to conduct sensitivity analyses. This paper's aim is to demonstrate how SEs around HRQoL values can be calculated, using the example of the UK EQ-5D-3L value set.

The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide.

The data sources and methods used to develop global cancer incidence and mortality statistics-the GLOBOCAN estimates-for the year 2022 are documented in this article, alongside a brief overview of the global cancer burden. The estimates, made available in 185 countries or territories worldwide for 36 cancer sites by sex and age, are based on the best available local data sources, namely population-based cancer registries (for incidence) and national vital statistics (for mortality). In males, lung cancer was the most commonly diagnosed cancer worldwide in 2022 (1.

Cancer in the Grand Libreville, Gabon (2013-2017).

Background: The burden of cancer is expected to nearly double in sub-Saharan Africa over the next 20 years. In Gabon, the primary population-based cancer registry to be established is located in the Grand Libreville. This study presents cancer incidence rates covering the first 5-year period of registration in this region.

Stage at diagnosis and survival among adult patients with cancer in Rwanda: A population-based study.

There are marked disparities in cancer survival in low-income countries compared to high-income countries, yet population-based data in the first is largely lacking. In this study, data from the national cancer registry of Rwanda were examined for 542 patients diagnosed with eight of the most common cancers of adults stomach (C16), colorectum (C18-20), liver (C22), breast (female) (C50), cervix (C53), ovary (C56), prostate (C61), and non-Hodgkin lymphomas (C82-85) between 2014 and 2017. Subjects were randomly selected for active followed-up to calculate 1-, 3-, and 5-year observed and relative survival (RS) by cancer type and stage.